Design and biological evaluation of novel, balanced dual PPARalpha/gamma agonists (Q27654470)

1

0 references

Agnes Bénardeau

2

0 references

Jörg Benz

3

0 references

Alfred Binggeli

4

0 references

Denise Blum

5

0 references

Hans Hilpert

6

0 references

Bernd Kuhn

7

0 references

Hans Peter Märki

8

0 references

Markus Meyer

9

0 references

Peter Mohr

10

0 references

Kurt Püntener

11

0 references

Susanne Raab

12

0 references

Armin Ruf

13

0 references

Daniel Schlatter

PPAR: a mediator of peroxisome proliferator action

14

0 references

language of work or name

1 reference

June 2009

0 references

published in

ChemMedChem

0 references

volume

4

0 references

issue

6

0 references

page(s)

951-6

0 references

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800425

Roles of PPAR delta in lipid absorption and metabolism: a new target for the treatment of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800425

Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800425

Banting lecture 1988. Role of insulin resistance in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800425

7 January 2021

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800425

7 January 2021

Insulin resistance syndrome and type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800425

7 January 2021

The PPARs: from orphan receptors to drug discovery

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800425

7 January 2021

Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800425

7 January 2021

The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800425

7 January 2021

Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800425

7 January 2021

Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monother

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800425

7 January 2021

The anti-apoptotic role of PPARβ contributes to efficient skin wound healing

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800425

7 January 2021

Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800425

7 January 2021

Selective PPARgamma modulators with improved pharmacological profiles

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800425

7 January 2021

The Protein Data Bank

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800425

7 January 2021

Molecular recognition of fatty acids by peroxisome proliferator-activated receptors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800425

7 January 2021

Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800425

7 January 2021

Structure of the PPARalpha and -gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800425

7 January 2021

Structure-based design of indole propionic acids as novel PPARalpha/gamma co-agonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800425

7 January 2021

Chronic and acute effects of thiazolidinediones BM13.1258 and BM15.2054 on rat skeletal muscle glucose metabolism

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800425

7 January 2021

A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800425

7 January 2021

A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800425

7 January 2021

Interactions with aromatic rings in chemical and biological recognition

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800425

7 January 2021

PAMPA--critical factors for better predictions of absorption

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800425

7 January 2021

hERG potassium channels and cardiac arrhythmia

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800425

7 January 2021

In silico prediction of brain and CSF permeation of small molecules using PLS regression models

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800425

7 January 2021

The influence of age on the development of hypertriglyceridaemia and hypercholesterolaemia in genetically diabetic mice

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800425

7 January 2021

The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800425

7 January 2021

Lipogenesis in situ in the genetically obese Zucker fatty rat (fa/fa): Role of hyperphagia and hyperinsulinaemia

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800425

7 January 2021

Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new high density lipoprotein size subclasses

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800425

7 January 2021

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800425

7 January 2021

Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800425

7 January 2021

release_xp2s7l52xjaajcjkx5firu3xxi

Identifiers

DOI

10.1002/CMDC.200800425

0 references

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xp2s7l52xjaajcjkx5firu3xxi

24 November 2022